Some were able to start speaking and even walking.
In the quiet architecture of the human brain, seven children carried a silence that was not chosen — their neurons intact, their will present, but the molecular key to movement missing entirely. At UCSF, researchers threaded a corrective gene into the precise chambers where dopamine is born, and in most of these children, the body began, slowly, to answer. The trial, published in Nature Communications in July 2021, stands as a reminder that some of medicine's most profound acts are not the conquest of disease, but the restoration of what was always meant to be there.
- Seven children with AADC deficiency arrived at UCSF unable to speak, hold their heads up, or feed themselves — their brains wired correctly but missing the single enzyme needed to produce dopamine.
- Surgeons used real-time MRI guidance to deliver a working copy of the AADC gene directly into the brainstem, a procedure never before attempted in children with this condition.
- Within months, the most distressing symptom — involuntary eye-locking crises lasting hours — disappeared in nearly all patients, and mood, mobility, and communication began to emerge.
- By the one-year mark, six of seven children had gained head control, four could sit unsupported, and one child who could not sit at the trial's start was walking independently two and a half years later.
- One child died seven months after surgery, likely from the underlying disease; the remaining six showed no significant adverse effects and sustained improvements over years.
- Emboldened by these results, the research team is now preparing gene therapy trials for early Alzheimer's disease and multiple system atrophy, using the same surgical delivery method.
Seven children between the ages of four and nine arrived at UCSF Benioff Children's Hospitals with a condition affecting roughly 135 people worldwide. AADC deficiency robs the brain of a single enzyme needed to manufacture dopamine — leaving children with intact neural architecture but no ability to move, speak, or feed themselves. Their minds were present. Their bodies would not follow.
In a trial led by neurosurgeon Krystof Bankiewicz, researchers made a small opening in each child's skull and used real-time MRI imaging to guide a catheter into the brainstem's dopamine-producing regions. A viral vector carrying a functional copy of the AADC gene was infused directly into the tissue. The team then waited.
The results, published in Nature Communications in July 2021, were striking. The involuntary eye-rolling episodes that had defined the children's daily suffering vanished in nearly all of them — and did not return. In the months that followed, parents described children who began to laugh, whose moods lifted, who started to speak. One child who could not sit independently at the trial's start took unassisted steps two and a half years after surgery. By twelve months, six of seven had gained head control; four could sit without support; one developed a vocabulary of roughly fifty words.
The underlying logic was straightforward: unlike Parkinson's disease, where dopamine neurons die, these children's neurons were structurally sound — they simply lacked the genetic instructions to do their work. Delivering those instructions restored function at the molecular level, confirmed by brain imaging and cerebrospinal fluid analysis showing elevated dopamine activity.
One child died seven months after the procedure, with researchers concluding the cause was most likely the underlying disease rather than the surgery itself. The remaining six experienced no significant adverse effects. For Bankiewicz's team, the success has opened a wider door: two new trials using the same surgical approach are now planned at Ohio State University — one targeting early Alzheimer's disease, another addressing multiple system atrophy. For families who had known only symptom management, the trial offered something rarer: the possibility of repair.
Seven children, ages four to nine, arrived at UCSF Benioff Children's Hospitals unable to speak, unable to feed themselves, unable to hold their heads upright. They had AADC deficiency, a rare genetic disorder affecting only about 135 children worldwide. The condition stems from a missing enzyme—AADC—that the brain needs to manufacture dopamine, the neurotransmitter that governs movement, mood, learning, and focus. Without it, these children were trapped in bodies that would not obey them.
In a trial that began at UCSF and extended to Ohio State Wexner Medical Center, researchers led by neurosurgeon Krystof Bankiewicz attempted something that had never been tried in children with this disease: they delivered a working copy of the AADC gene directly into the brain. The procedure involved making a small hole in the skull and using real-time MRI imaging to guide a catheter to precise regions of the brainstem—the substantia nigra and ventral tegmental area—where dopamine-producing neurons live. A viral vector carrying the gene was infused into the tissue. Then the surgeons waited to see what would happen.
What happened, according to results published in Nature Communications in July 2021, was striking. The oculogyric crises—episodes in which the eyes roll upward involuntarily and lock in place for hours, sometimes accompanied by seizure-like activity—vanished in all but one child. These episodes, a hallmark of the disease, were the first symptoms to disappear after surgery and never returned. In the months that followed, parents and caregivers reported changes that seemed to reshape their children's lives. Some children began to laugh. Their moods lifted. A few started to speak. One child, who could not sit independently at the start of the trial, took independent steps two and a half years after surgery.
By the twelve-month mark, six of the seven children had gained head control—a basic motor skill that had been beyond their reach. Four could sit without support. Three could reach and grasp objects. Two could walk with trunk support. One child developed a vocabulary of about fifty single words. Another learned to communicate using an assistive device. Sleep improved across the group. Feeding difficulties eased. The irritability that had characterized most of the children at baseline gave way to better mood and fuller interaction with parents and siblings.
The mechanism was elegant in its simplicity. Unlike Parkinson's disease, where dopamine-producing neurons degenerate over time, children with AADC deficiency have intact neural wiring—their brains are normally constructed. The problem is that their neurons lack the instructions to make dopamine. By delivering the AADC gene directly to those neurons, the researchers essentially gave them back the ability to do what they were built to do. Brain imaging after surgery showed increased AADC activity, and analysis of cerebrospinal fluid revealed elevated concentrations of dopamine metabolites, confirming that the treatment was working at the molecular level.
The trial was not without cost. One child died seven months after surgery. The researchers noted that the child appeared to be in good health at the time and concluded the death was most likely due to the underlying disease itself rather than the procedure. The surgery was otherwise well tolerated, with no significant short-term or long-term adverse effects reported in the other six children.
Bankiewicz and his team had adapted techniques they had pioneered in treating Parkinson's disease, where the same enzyme deficiency plays a role. The success in these seven children has opened new possibilities. The researchers are now launching two additional gene therapy trials using the same surgical approach and viral vector—one for early Alzheimer's disease and another for multiple system atrophy, a rare neurodegenerative disorder. Both trials are set to begin at Ohio State University. For families of children with AADC deficiency, a condition that has long been managed only through symptom control with medications and supportive care, the results suggest that a more fundamental intervention—restoring the missing piece of the genetic puzzle—may be possible.
Notable Quotes
In AADC deficiency, the wiring of the brain is normal, it's just the neurons don't know how to produce dopamine because they lack AADC.— Krystof Bankiewicz, neurosurgeon, UCSF
These episodes were the first to disappear and they never returned. In the months that followed, many patients experienced life-changing improvements.— Krystof Bankiewicz
The Hearth Conversation Another angle on the story
What made this trial different from just giving these children dopamine-boosting drugs, which doctors had already been doing?
The medications they were on—Parkinson's drugs, melatonin, benzodiazepines—they were treating symptoms, not the root cause. A child still couldn't speak or walk. This gene therapy actually restored the brain's ability to make dopamine on its own, which is fundamentally different.
Why did the oculogyric crises disappear first, before the motor improvements?
That's what struck the surgeons too. Those episodes stopped almost immediately after surgery and never came back. The motor gains took longer—months to develop. It suggests the brain was responding to dopamine availability in different ways depending on the circuit involved.
One child died. How do you talk about that alongside the dramatic improvements in the others?
You don't minimize it. The researchers were honest that it likely came from the underlying disease, not the procedure itself. But it's a reminder that even when something works, it doesn't work for everyone. Six families had their children's lives transformed. One family lost their child. Both things are true.
These are very young children. How do you measure improvement in a four-year-old who couldn't speak before?
You watch what they do. Can they hold their head up? Can they sit? Can they reach for a toy? Can they laugh? Can they say words? The parents and caregivers saw these things happen. That's the measurement.
Why is this technique now being tested for Alzheimer's and other diseases?
Because the principle works: if you can get a working gene into the right part of the brain using real-time imaging, you can restore function. The technique isn't specific to AADC deficiency. It's a tool that might work wherever a missing or broken gene is causing neurological disease.